NMR-based functional profiling of RASopathies and oncogenic RAS mutations

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 12, 2013, Pages 4574-4579

  Smith, Matthew J ^a   Neel, Benjamin G ^a   Ikura, Mitsuhiko ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Guanine nucleotide exchange factor inhibition; Nuclear magnetic resonance; Real time bioassay

Indexed keywords

CELL EXTRACT; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATE; LEUCINE; NEUROFIBROMIN; NUCLEOTIDE; ONCOPROTEIN; RAS PROTEIN; REGULATOR PROTEIN; SOS PROTEIN;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CATALYSIS; CELL ASSAY; CELL MEMBRANE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; HYDROLYSIS; MAMMAL CELL; MUTANT; NONHUMAN; NOONAN SYNDROME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; WILD TYPE;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; MUTATION, MISSENSE; NEOPLASMS; NEUROFIBROMATOSIS 1; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; ONCOGENE PROTEIN P21(RAS); SIGNAL TRANSDUCTION;

EID: 84875233112     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218173110     Document Type: Article

References (39)

1. Fernández-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2(3):344-358.
2. Gysin S, Salt M, Young A, McCormick F (2011) Therapeutic strategies for targeting Ras proteins. Genes Cancer 2(3):359-372.
3. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1):11-22.
4. Rodriguez-Viciana P, Sabatier C, McCormick F (2004) Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24 (11):4943-4954.
5. Der CJ, Finkel T, Cooper GM (1986) Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44(1):167-176.
6. Gibbs JB, Sigal IS, Poe M, Scolnick EM (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 81(18):5704-5708.
7. McGrath JP, Capon DJ, Goeddel DV, Levinson AD (1984) Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310(5979): 644-649.
8. Manne V, Bekesi E, Kung HF (1985) Ha-ras proteins exhibit GTPase activity: Point mutations that activate Ha-ras gene products result in decreased GTPase activity. Proc Natl Acad Sci USA 82(2):376-380.
9. Bollag G, McCormick F (1991) Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature 351(6327):576-579.
10. Scheffzek K, et al. (1997) The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277(5324):333-338.
11. Guerrero S, et al. (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60(23):6750-6756.
12. Morelli MP, Kopetz S (2012) Hurdles and complexities of codon 13 KRAS mutations. J Clin Oncol 30(29):3565-3567.
13. Tidyman WE, Rauen KA (2009) The RASopathies: Developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 19(3):230-236.
14. Legius E, Marchuk DA, Collins FS, Glover TW (1993) Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 3(2):122-126.
15. Bollag G, et al. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12(2):144-148.
16. Roberts AE, et al. (2007) Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39(1):70-74.
17. Tartaglia M, et al. (2007) Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39(1):75-79.
18. Marshall CB, et al. (2012) Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts. Methods 57(4):473-485.
19. Mazhab-Jafari MT, et al. (2010) Real-time NMR study of three small GTPases reveals that fluorescent 2'(3')-O-(N-methylanthraniloyl)-tagged nucleotides alter hydrolysis and exchange kinetics. J Biol Chem 285(8):5132-5136.
20. Temeles GL, Gibbs JB, D'Alonzo JS, Sigal IS, Scolnick EM (1985) Yeast and mammalian Ras proteins have conserved biochemical properties. Nature 313(6004):700-703.
21. Margarit SM, et al. (2003) Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112(5):685-695.
22. Gideon P, et al. (1992) Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: The C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol 12(5):2050-2056.
23. The I, et al. (1993) Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet 3(1):62-66.
24. Johnson MR, Look AT, DeClue JE, Valentine MB, Lowy DR (1993) Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci USA 90(12):5539-5543.
25. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR (2001) Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 158(2):501-513.
26. Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T (2003) Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev 17(4): 449-454.
27. Gureasko J, et al. (2010) Role of the histone domain in the autoinhibition and activation of the Ras activator Son of sevenless. Proc Natl Acad Sci USA 107(8):3430-3435.
28. Sondermann H, et al. (2004) Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell 119(3):393-405.
29. Yadav KK, Bar-Sagi D (2010) Allosteric gating of Son of sevenless activity by the histone domain. Proc Natl Acad Sci USA 107(8):3436-3440.
30. Freedman TS, et al. (2006) A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc Natl Acad Sci USA 103(45):16692-16697.
31. Lepri F, et al. (2011) SOS1 mutations in Noonan syndrome: Molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat 32(7):760-772.
32. Scheffler JE, et al. (1994) Characterization of a 78-residue fragment of c-Raf-1 that comprises a minimal binding domain for the interaction with Ras-GTP. J Biol Chem 269(35):22340-22346.
33. Herrmann C, Martin GA, Wittinghofer A (1995) Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 270(7):2901-2905.
34. Filchtinski D, et al. (2010) What makes Ras an efficient molecular switch: A computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf. J Mol Biol 399(3):422-435.
35. Guerrero S, et al. (2002) Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J 16(12):1642-1644.
36. Basu TN, et al. (1992) Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356(6371):713-715.
37. Leondaritis G, Petrikkos L, Mangoura D (2009) Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: Implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation. J Neurochem 109(2):573-583.
38. Gureasko J, et al. (2008) Membrane-dependent signal integration by the Ras activator Son of sevenless. Nat Struct Mol Biol 15(5):452-461.
39. Sacco E, et al. (2012) Regulation of hSos1 activity is a system-level property generated by its multi-domain structure. Biotechnol Adv 30(1):154-168.